Influence of CYP2C19 Polymorphism on Lansoprazole and Rabeprazole Maintenance Treatment of Reflux Esophagitis

被引：0
|
作者：
Koike, Tomoyuki
Iijima, Katsunori
Imatani, Akira
Shimosegawa, Tooru
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W1117
引用
收藏
页码：S655 / S655
页数：1
相关论文
共 50 条
  • [41] Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication
    Ozdil, Burhan
    Akkiz, Hikmet
    Bayram, Suleyman
    Bekar, Aynur
    Akgollu, Ersin
    Sandikci, Macit
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (01): : 23 - 28
  • [42] CYP2C19 gene polymorphism in Ningxia
    Zhen Yang
    Yunqian Xie
    Daya Zhang
    Yan Zou
    Ximei Li
    Runxiang Chen
    Xiaodong Zhang
    Shiju Chen
    Feihu Bai
    Pharmacological Reports, 2023, 75 : 705 - 714
  • [43] CYP2C19 gene polymorphism in Ningxia
    Yang, Zhen
    Xie, Yunqian
    Zhang, Daya
    Zou, Yan
    Li, Ximei
    Chen, Runxiang
    Zhang, Xiaodong
    Chen, Shiju
    Bai, Feihu
    PHARMACOLOGICAL REPORTS, 2023, 75 (03) : 705 - 714
  • [44] Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism
    Medina J.F.
    Lecanda J.
    Acín A.
    Ciesielczyk P.
    Prieto J.
    European Journal of Clinical Pharmacology, 2001, 57 (6) : 485 - 492
  • [45] Influence of CYP2C19 Polymorphism on the Gut Microbiome in Helicobacter pylori-Negative Healthy Individuals Receiving Vonoprazan and Lansoprazole
    Otsuka, Taketo
    Sugimoto, Mitsushige
    Inoue, Ryo
    Ohno, Masashi
    Ban, Hiromitsu
    Nishida, Atsushi
    Inatomi, Osamu
    Naito, Yuji
    Andoh, Akira
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S678 - S678
  • [46] Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism
    Ieiri, I
    Kishimoto, Y
    Okochi, H
    Momiyama, K
    Morita, T
    Kitano, M
    Morisawa, T
    Fukushima, Y
    Nakagawa, K
    Hasegawa, J
    Otsubo, K
    Ishizaki, T
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (6-7) : 485 - 492
  • [47] The Association Between CYP2C19 Gene Polymorphism and Response to Treatment With Pantoprazole in Patients With Gastroesophageal Reflux Disease
    Altinbas, Akif
    Ekiz, Fuat
    Goktas, Mustafa
    Karaca, Ozgur
    Yilmaz, Baris
    Yasar, Umit
    Coban, Sahin
    Babaoglu, Melih
    Bozkurt, Atilla
    Yuksel, Osman
    GASTROENTEROLOGY, 2013, 144 (05) : S859 - S859
  • [48] Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects
    Zhang, Dan
    Wang, Xiaolin
    Yang, Man
    Wang, Guocai
    Liu, Huichen
    XENOBIOTICA, 2011, 41 (06) : 511 - 517
  • [49] CYP2C19 genotype does not have a significant pharmacokinetic influence in sodium rabeprazole.
    Aoyama, N
    Sakai, T
    Sakaeda, T
    Shirasaka, D
    Miyamoto, M
    Kasuga, M
    GASTROENTEROLOGY, 2000, 118 (04) : A1211 - A1211
  • [50] The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole
    Bekkers, CHJ
    Touw, DJ
    Lamers, CBHW
    Geus, WP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 553 - 553
12345